DSGN Quick Ratio | Design Therapeutics, Inc.

Design Therapeutics, Inc. Quick Ratio

The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

Design Therapeutics, Inc. quick ratio for the quarter ending 2026-06-30 was 18.45, a 25.37% decline year-over-year.
Design Therapeutics, Inc. quick ratio for the quarter ending 2026-03-31 was 21.87, a 21.59% decline year-over-year.
Design Therapeutics, Inc. quick ratio for the quarter ending 2025-12-31 was 16.84, a 41.95% decline year-over-year.
Design Therapeutics, Inc. quick ratio for the quarter ending 2025-09-30 was 18.43, a 46.08% decline year-over-year.
Design Therapeutics, Inc. quick ratio for fiscal 2025 was 16.84, a 41.95% decline from fiscal 2024.
Design Therapeutics, Inc. quick ratio for fiscal 2024 was 29.01, a 0.95% decline from fiscal 2023.
Design Therapeutics, Inc. quick ratio for fiscal 2023 was 29.29, a 4.48% decline from fiscal 2022.
Design Therapeutics, Inc. quick ratio for fiscal 2022 was 30.66, a 57.83% decline from fiscal 2021.

Available history: 2020-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical Quick Ratio

Date	Quick Ratio	Quick assets	Current liabilities
2026-06-30	18.45	$207.4M	$11.24M
2026-03-31	21.87	$222.82M	$10.19M
2025-12-31	16.84	$219.85M	$13.06M
2025-09-30	18.43	$205.97M	$11.17M
2025-06-30	24.73	$216.28M	$8.75M
2025-03-31	27.89	$229.67M	$8.24M
2024-12-31	29.01	$245.48M	$8.46M
2024-09-30	34.19	$254.07M	$7.43M
2024-06-30	40.82	$261.02M	$6.39M
2024-03-31	38.16	$270.69M	$7.09M
2023-12-31	29.29	$281.8M	$9.62M
2023-09-30	23.48	$290.94M	$12.39M
2023-06-30	24.98	$303.09M	$12.13M
2023-03-31	34.86	$315.39M	$9.05M
2022-12-31	30.66	$330.39M	$10.78M
2022-09-30	33.06	$344.23M	$10.41M
2022-06-30	48.64	$359.38M	$7.39M
2022-03-31	67.74	$371.22M	$5.48M
2021-12-31	72.7	$384.06M	$5.28M
2021-09-30	71.52	$393.72M	$5.51M
2021-06-30	118.31	$402.84M	$3.41M
2021-03-31	110.99	$411.34M	$3.71M
2020-12-31	15.49	$36.09M	$2.33M

Annual Quick Ratio

Date	Quick Ratio	Quick assets	Current liabilities
2025-12-31	16.84	$219.85M	$13.06M
2024-12-31	29.01	$245.48M	$8.46M
2023-12-31	29.29	$281.8M	$9.62M
2022-12-31	30.66	$330.39M	$10.78M
2021-12-31	72.7	$384.06M	$5.28M
2020-12-31	15.49	$36.09M	$2.33M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Wave Life Sciences, Inc. (WVE)		$0.780B	-5.56
Faeth Therapeutics, Inc. (FTH)	United States	$0.750B
Olema Pharmaceuticals, Inc. (OLMA)	United States	$0.790B	-5.35
Aclaris Therapeutics, Inc. (ACRS)	United States	$0.792B	-9.78
COLLEGIUM PHARMACEUTICAL, INC (COLL)	United States	$0.737B	24.57
GERON CORP (GERN)	United States	$0.803B	-12.14
GYRE THERAPEUTICS, INC. (GYRE)	United States	$0.818B	-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)	United States	$0.823B	-17.48
Verastem, Inc. (VSTM)	United States	$0.706B	-1.71
Nuvectis Pharma, Inc. (NVCT)	United States	$0.705B	-17.53